Wong, M. H., Jones, V. C., Yu, W., Bosserman, L. D., Lavasani, S. M., Patel, N., . . . Mortimer, J. E. UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan. Wiley.
Chicago Style (17th ed.) CitationWong, Megan H., et al. UGT1A1*28 Polymorphism and the Risk of Toxicity and Disease Progression in Patients with Breast Cancer Receiving Sacituzumab Govitecan. Wiley.
MLA (9th ed.) CitationWong, Megan H., et al. UGT1A1*28 Polymorphism and the Risk of Toxicity and Disease Progression in Patients with Breast Cancer Receiving Sacituzumab Govitecan. Wiley.
Warning: These citations may not always be 100% accurate.